



Ventripoint Diagnostics Issues Shares in Payment of Consulting Fees

Toronto, Ontario – The Newswire – January 18, 2021 - Ventripoint Diagnostics Ltd. ("**Ventripoint**" or the "**Company**"), (TSXV:VPT; OTC:VPTDF) announces it will issue an aggregate of 666,666 shares to a consultant for \$60,000 in consulting fees at a deemed price of \$0.09 per share, which was the closing share price on September 30, 2020 and December 31, 2020 when the fees were due and payable.

The above issuance of shares is subject to the approval of the TSXV Exchange.

About Ventripoint Diagnostics Ltd.

Ventripoint has become an industry leader in the application of AI (Artificial Intelligence) to echocardiography. Ventripoint's VMS products are powered by its proprietary KBR technology, which is the result of a decade of development and provides accurate volumetric cardiac measurements equivalent to MRI. This affordable, gold-standard alternative allows cardiologists greater confidence in the management of their patients. Providing better care to patients serves as a springboard and basic standard for all of Ventripoint's products that guide our future developments. In addition, VMS+ is versatile and can be used with all ultrasound systems from any vendor supported by regulatory market approvals in the U.S., Europe and Canada.

For further information, please contact:

Dr. George Adams
Email: gadams@ventripoint.com
Phone: 519-803-6937

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this news release.